Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
NCT ID: NCT06607757
Last Updated: 2025-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2024-12-04
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
120 patients will be randomized to receive:
\- Capivasertib (400 mg po twice daily d1-4 followed by 3 days off) for 2 weeks followed by capivasertib (400 mg po twice daily d1-4 followed by 3 days off) and fulvestrant (500 mg i.m. q28d, with an additional 500 mg dose given two weeks after the initial dose) for additional 8 weeks (overall 4 administrations of fulvestrant)
or
\- Fulvestrant (500mg i.m. q28d, with an additional 500 mg dose given two weeks after the core biopsy and the initial dose) for 10 weeks (overall 4 administrations) Treatment will be given until surgery/core-biopsy, disease progression, unacceptable toxicity, or withdrawal of consent of the patient.
All patients will undergo core-biopsies, under treatment and after completing study therapy in order to assess Ki67%. Further treatment including surgery, (neo)adjuvant chemotherapy, radiotherapy, and (neo)adjuvant endocrine therapy will be administered at the discretion of the investigator and according to standard of care outside the clinical trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
NCT00534417
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
NCT01441947
Effect of Capivasertib on ctDNA in ER Positive Breast Cancer
NCT06613516
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
NCT00721630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The addition of capivasertib to fulvestrant in many clinical trials correlates with an improvement in PFS compared to fulvestrant alone in patients with HR+/HER2- locally advanced or metastatic breast cancer. This effect was observed regardless of a PI3K/AKT/mTOR pathway activation. None of the ongoing studies investigate the effects of the combined treatment in invasive lobular breast cancer. Given that these tumors are less likely to respond to chemotherapy, identification of patients that can be spared from chemotherapy is desirable. On the other hand, it is important to identify patients with invasive lobular breast cancer not responding to neoadjuvant ET who might be at increased risk for recurrence, who would therefore potentially benefit from further adjuvant therapies including chemotherapy.
Given the high rates of PI3K pathway alterations in such tumors, it is expected that the CCCA rate could be increased by adding capivasertib to fulvestrant. GBG expect that the potential benefit of improved CCCA rate with a combination treatment compared to fulvestrant monotherapy would outweigh the potential risks due to added toxicity, which has already been shown in clinical trials to be well tolerated by patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Capivasertib (400 mg po twice daily d1-4 followed by 3 days off) for 2 weeks followed by capivasertib (400 mg po twice daily d1-4 followed by 3 days off) and fulvestrant (500 mg i.m. q28d, with an additional 500 mg dose given two weeks after the initial dose) for additional 8 weeks (overall 4 administrations of fulvestrant)
Capivasertib
find arm A description
Fulvestrant injection
find arm B description
Arm B
Fulvestrant (500mg i.m. q28d, with an additional 500 mg dose given two weeks after the core biopsy and the initial dose) for 10 weeks (overall 4 administrations)
Fulvestrant injection
find arm B description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Capivasertib
find arm A description
Fulvestrant injection
find arm B description
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Postmenopausal women with age at diagnosis ≥ 18 years.
Postmenopausal status is defined as:
* Age ≥60 years
* Age \<60 years and amenorrhea for at least 12 continuous months with no identified cause other than menopause
* Bilateral oophorectomy Negative pregnancy test (urine or serum) within 14 days prior to randomization for all postmenopausal women 50 years of age or younger without bilateral oophorectomy
4. Willingness and ability to provide archived formalin fixed paraffin embedded (FFPE) tissue block from core biopsy before the start of neoadjuvant therapy.
5. Centrally confirmed HER2-negative (IHC score 0-1+ or ISH negative according to ASCO/CAP guideline) and HR-positive (≥10% positive stained cells) disease, assessed on the core of diagnostic biopsy. Ki67% \>10% is required. In case of bilateral breast cancer, HER2-negative, HR-positive and lobular histology status has to be confirmed for both sides.
6. Patients with invasive lobular breast cancer at high risk for recurrence defined as cT1c and clinical nodal involvement (cN+) or ≥ cT2 disease (irrespective of nodal involvement).
7. No clinical evidence of distant metastases.
8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
9. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer.
10. The patient must be accessible for scheduled visits, treatment, and followup.
11. Normal cardiac function must be confirmed according to local guidelines.
12. Laboratory requirements:
Hematology
* Absolute neutrophil count (ANC) ≥1.5 x 109 / L
* Platelets ≥100 x 109 / L
* Hemoglobin ≥10 g/dL (≥6.2 mmol/L) Hepatic function
* Total bilirubin \<1.25x ULN
* AST and ALT \<=1.5x ULN
* Alkaline phosphatase \<=2.5x ULN Glucose Metabolism
* HbA1c \<8.0% (63.9 mmol/mol) Renal Function
* Creatinine \<1.25x ULN or creatinine clearance ≥50 ml/min (if creatinine is above ULN according to Cockroft-Gault)
13. Complete staging work-up prior to the initiation of neoadjuvant therapy as per standard recommendations.
Exclusion Criteria
2. Excisional biopsy or lumpectomy performed prior to study entry.
3. Surgical axillary staging procedure including sentinel lymph node biopsy prior to randomization. Exceptions: FNA or core biopsy of an axillary lymph node.
4. Any previous treatment including endocrine therapy, chemotherapy, radiotherapy or targeted therapy (including AKT inhibitor or PIK3 inhibitor) for the currently diagnosed breast cancer.
5. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer.
6. Known hypersensitivity reaction to one of the compounds or substances used in this protocol.
7. Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort).
8. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of capivasertib.
9. Any contraindication for fulvestrant.
10. Patients with definitive clinical or radiologic evidence of stage IV cancer (metastatic disease) are not eligible.
11. Patients with a history of any malignancy are ineligible with the following exceptions:
* Patient has been disease-free for at least 5 years and is at low risk for recurrence of that malignancy except for breast cancer.
* CIS of the cervix, basal cell and squamous cell carcinomas of the skin.
12. History of type I or type II diabetes mellitus requiring insulin.
13. Severe and relevant co-morbidity that would interact with the application of study drugs or the participation in the study, including cerebrovascular incident including transient ischemic attack, or symptomatic pulmonary embolism, active infection requiring intravenous anti-microbial treatment (antibiotics, anti-fungal, and anti-viral drugs) within 1 week of enrolment. Patients with confirmed Gilbert's syndrome may be included in the study.
14. Known medically history of HIV infection, tuberculosis, or hepatitis B.
15. History of and/or active cardiac disease that would preclude the use of study treatments. This includes but is not confined to any of the following cardiac criteria:
* Clinically significant cardiac dysfunction including heart failure (NYHA II-IV), active ventricular arrhythmias requiring medication or arrhythmias requiring a pacemaker, and history of a myocardial infarction within 6 months prior to randomization, angina pectoris, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, angioplasty, or vascular stent.
* Mean resting QT interval corrected by Fridericia's formula (QTcF) \>470 msec obtained from 3 consecutive ECGs.
* Increased risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncontrolled electrolyte disorders (e.g., hypocalcemia, hypokalemia, or hypomagnesemia), potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval.
16. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving therapy.
17. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent.
18. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension or hypotension (BP \<50mmHg), significant aneurysm, renal transplant and active bleeding diseases).
19. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
20. Participation in another clinical study with a study intervention or investigational medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
GBG Forschungs GmbH
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sibylle Loibl, Prof. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
ESMO, ASCO, AGO Kommission Mamma (member); Goethe University Frankfurt; GBG Forschungs GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Haematologie-Onkologie im Zentrum MVZ GmbH
Augsburg, , Germany
Charité
Berlin, , Germany
Onkologische Schwerpunktpraxis - Studiengesellschaft Onkologie Bielefeld GbR
Bielefeld, , Germany
Hämato-Onkologie im Medicum - Onkologie und Hämatologie
Bremen, , Germany
Kliniken der Stadt Köln GmbH - Brustzentrum Köln-Holweide
Cologne, , Germany
Carl-Thiem-Klinikum gGmbH - Frauenklinik
Cottbus, , Germany
Kath. St. Paulus GmbH - Klinische Forschung
Dortmund, , Germany
Universitätsklinikum Essen - Klinik für Frauenheilkunde und Geburtshilfe
Essen, , Germany
Klinikum Frankfurt Höchst GmbH - Klinik für Gynäkologie und Geburtshilfe
Frankfurt am Main, , Germany
Praxis für Interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, , Germany
Mammazentrum Hamburg - am Krankenhaus Jerusalem
Hamburg, , Germany
Universitätsklinikum des Saarlandes - Frauenklinik
Homburg, , Germany
Klinikum Kassel GmbH - Frauenklinik
Kassel, , Germany
St. Elisabethen-Krankenhaus gGmbH - Senologie / Brustzentrum
Leipzig, , Germany
Medizinisches Versorgungszentrum MediaVita GmbH Muenster
Münster, , Germany
Klinikum Oldenburg AöR - Universitätsklinik für Innere Medizin - Onkologie
Oldenburg, , Germany
MVZ für Hämatolgie und Onkologie Ravensburg GmbH - Studienzentrum
Ravensburg, , Germany
Klinikum Südstadt - Universitätsfrauenklinik
Rostock, , Germany
Leopoldina-Krankenhaus der Stadt Schweinfurt - Frauenklinik
Schweinfurt, , Germany
Johanniter-Krankenhaus Genthin-Stendal - Klinik für Frauenheilkunde und Geburtshilfe
Stendal, , Germany
Kreiskrankenhaus Torgau - Gynäkologie
Torgau, , Germany
Praxisnetzwerk Haematologie und internistische Onkologie Ueberoertliche Berufsausuebungsgemeinschaft - Hämatologie und Onkologie
Troisdorf, , Germany
Marienhospital Witten - Brustzentrum
Witten, , Germany
Klinikum Worms gGmbH - Frauenklinik
Worms, , Germany
Helios Klinikum Wuppertal GmbH - Landesfrauenklinik
Wuppertal, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open. 2024 Sep;9(9):103697. doi: 10.1016/j.esmoop.2024.103697. Epub 2024 Sep 5.
Related Links
Access external resources that provide additional context or updates about the study.
GBG Website with information about LOBSTER Trial
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509292-17-00
Identifier Type: CTIS
Identifier Source: secondary_id
GBG118 - LOBSTER
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.